Opinion|Videos|January 11, 2024
Key Takeaways from SABCS 2023 in HER2+ Breast Cancer
Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers discuss their key takeaways on recent updates in HER2+ breast cancer.
Advertisement
Advertisement
Related to this article
Catch up on October 2026 FDA oncology actions: approvals for pirtobrutinib, tucatinib, and dostarlimab, plus BLA and NDA submissions and a new designation.
Late-breaking ESMO 2026 data show PFS gains with 3 antibody-drug conjugates, a 6-year OS benefit with adjuvant ribociclib, and no OS gain with pembrolizumab.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Finalizes Potency Guidance for Cell and Gene Therapy Products
3
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
4
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
5